Article Sidebar
Published:
Mar 12, 2019Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Therapeutic effect of co-administered salvianolate and atorvastatin calcium on coronary heart disease patients with angina pectoris, and their blood lipid levels
Abstract
Purpose: To investigate the clinical effect of combination of salvianolate and atorvastatin on blood lipids of coronary heart disease patients with angina pectoris (CHD-AP).
Method: Patients with CHD-AP (n = 104) from January 2016 to January 2017 were randomly assigned to two groups: control group treated with atorvastatin (10 mg/day), and study group was administered atorvastatin (10 mg/day, oral) plus salvianolate (200 mg/day in 5 % glucose, iv). Palpitation, chest distress, improvement in myocardial ischemia, myocardial function, and hemodynamics were determined and used to assess treatment effectiveness in the two groups. Differences in blood lipid profiles were also investigated.
Results: Improvement in palpitation, chest distress, myocardial ischemia and myocardial function in the study group were significantly higher than in the control group (p < 0.05). In the study group, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triacylglycerols (TGs) significantly decreased, relative to the control group (p < 0.05).
Conclusion: Treatment of CHD-AP patients with combination of salvianolate and atorvastatin significantly ameliorates coronary heart disease and angina pectoris, and also reduces their blood lipid levels.
Keywords: Salvianolate, Atorvastatin, Coronary heart disease, Angina pectoris, Blood lipids
